Repare Therapeutics
- Country
- πΊπΈUnited States
- Ownership
- Private
- Employees
- 179
- Market Cap
- $128.6M
- Introduction
Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded on September 6, 2016 and is headquartered in Saint-Laurent, Canada.
Phase 1 Trial of RP-3467 Alone and in Combination with Olaparib in Participants with Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Repare Therapeutics
- Target Recruit Count
- 52
- Registration Number
- NCT06560632
- Locations
- πΊπΈ
Participating Site #1025, San Francisco, California, United States
πΊπΈParticipating Site # 1008, New York, New York, United States
πΊπΈParticipating Site # 1004, New York, New York, United States
LIONS (PLK4 Inhibitor in Advanced Solid Tumors)
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Repare Therapeutics
- Target Recruit Count
- 80
- Registration Number
- NCT06232408
- Locations
- π©π°
Participating Site 4001, Copenhagen, Denmark
πΊπΈParticipating Site 1025, San Francisco, California, United States
πΊπΈParticipating Site 1012, New Haven, Connecticut, United States
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Repare Therapeutics
- Target Recruit Count
- 104
- Registration Number
- NCT05147272
- Locations
- πΊπΈ
Participating site # 1017, Jacksonville, Florida, United States
πΊπΈParticipating Site # 1023, Grand Rapids, Michigan, United States
πΊπΈParticipating Site # 1008, New York, New York, United States
Study of RP-6306 with FOLFIRI in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Repare Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT05147350
- Locations
- πΊπΈ
Site 1022, Tampa, Florida, United States
πͺπΈSite 5002, Madrid, Spain
πͺπΈSite 5003, Madrid, Spain
Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Repare Therapeutics
- Target Recruit Count
- 196
- Registration Number
- NCT04972110
- Locations
- πΊπΈ
Participating Site #1009, Baltimore, Maryland, United States
πΊπΈParticipating Site # 1001, Houston, Texas, United States
πΊπΈParticipating Site # 1013, Salt Lake City, Utah, United States
Study of RP-6306 Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Repare Therapeutics
- Target Recruit Count
- 364
- Registration Number
- NCT04855656
- Locations
- π©π°
Participating Site #4001, Copenhagen, Denmark
πΊπΈParticipating Site # 1004, New York, New York, United States
πΊπΈParticipating Site # 1001, Houston, Texas, United States
Study of RP-3500, Camonsertib, in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Repare Therapeutics
- Target Recruit Count
- 285
- Registration Number
- NCT04497116
- Locations
- πΊπΈ
Participating Site 1014, Chicago, Illinois, United States
πΊπΈParticipating Site 1006, Boston, Massachusetts, United States
πΊπΈParticipating Site 1001, Houston, Texas, United States